vs

Side-by-side financial comparison of LXP Industrial Trust (LXP) and MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI). Click either name above to swap in a different company.

LXP Industrial Trust is the larger business by last-quarter revenue ($86.7M vs $49.9M, roughly 1.7× MARAVAI LIFESCIENCES HOLDINGS, INC.). LXP Industrial Trust runs the higher net margin — 33.2% vs -71.6%, a 104.7% gap on every dollar of revenue. On growth, MARAVAI LIFESCIENCES HOLDINGS, INC. posted the faster year-over-year revenue change (-11.8% vs -14.0%). Over the past eight quarters, LXP Industrial Trust's revenue compounded faster (0.3% CAGR vs -11.9%).

LXP Industrial Trust is a publicly traded real estate investment trust (REIT) that owns, operates, and invests in high-quality industrial real estate assets, primarily distribution centers, logistics facilities, and light industrial properties across key markets in the United States. Its tenant base covers e-commerce, third-party logistics, and advanced manufacturing sectors, delivering stable long-term returns for its investors.

Maravai LifeSciences Holdings is a global life sciences firm developing critical reagents, diagnostic products, and tech solutions to support biopharma research, drug development, clinical diagnostics, and cell/gene therapy manufacturing. It serves biotech, pharma, research bodies and labs worldwide across three core segments.

LXP vs MRVI — Head-to-Head

Bigger by revenue
LXP
LXP
1.7× larger
LXP
$86.7M
$49.9M
MRVI
Growing faster (revenue YoY)
MRVI
MRVI
+2.2% gap
MRVI
-11.8%
-14.0%
LXP
Higher net margin
LXP
LXP
104.7% more per $
LXP
33.2%
-71.6%
MRVI
Faster 2-yr revenue CAGR
LXP
LXP
Annualised
LXP
0.3%
-11.9%
MRVI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LXP
LXP
MRVI
MRVI
Revenue
$86.7M
$49.9M
Net Profit
$28.8M
$-35.7M
Gross Margin
81.5%
25.8%
Operating Margin
34.6%
-117.9%
Net Margin
33.2%
-71.6%
Revenue YoY
-14.0%
-11.8%
Net Profit YoY
-37.7%
EPS (diluted)
$-0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LXP
LXP
MRVI
MRVI
Q4 25
$86.7M
$49.9M
Q3 25
$86.9M
$41.6M
Q2 25
$87.7M
$47.4M
Q1 25
$88.9M
$46.9M
Q4 24
$100.9M
$56.6M
Q3 24
$85.6M
$69.0M
Q2 24
$85.8M
$69.4M
Q1 24
$86.3M
$64.2M
Net Profit
LXP
LXP
MRVI
MRVI
Q4 25
$28.8M
$-35.7M
Q3 25
$36.3M
$-25.6M
Q2 25
$29.1M
$-39.6M
Q1 25
$19.0M
$-29.9M
Q4 24
$-25.9M
Q3 24
$6.3M
$-97.1M
Q2 24
$5.4M
$-9.8M
Q1 24
$-269.0K
$-12.1M
Gross Margin
LXP
LXP
MRVI
MRVI
Q4 25
81.5%
25.8%
Q3 25
82.3%
13.6%
Q2 25
81.9%
16.4%
Q1 25
80.7%
16.5%
Q4 24
85.3%
34.3%
Q3 24
82.5%
46.7%
Q2 24
82.0%
44.4%
Q1 24
82.4%
40.3%
Operating Margin
LXP
LXP
MRVI
MRVI
Q4 25
34.6%
-117.9%
Q3 25
50.4%
-98.6%
Q2 25
33.7%
-139.8%
Q1 25
21.8%
-104.9%
Q4 24
-66.7%
Q3 24
7.9%
-239.9%
Q2 24
6.9%
-19.4%
Q1 24
1.0%
-29.4%
Net Margin
LXP
LXP
MRVI
MRVI
Q4 25
33.2%
-71.6%
Q3 25
41.7%
-61.4%
Q2 25
33.2%
-83.5%
Q1 25
21.4%
-63.9%
Q4 24
-45.8%
Q3 24
7.4%
-140.6%
Q2 24
6.3%
-14.1%
Q1 24
-0.3%
-18.8%
EPS (diluted)
LXP
LXP
MRVI
MRVI
Q4 25
$-0.24
Q3 25
$0.12
$-0.18
Q2 25
$0.09
$-0.27
Q1 25
$0.06
$-0.21
Q4 24
$-0.21
Q3 24
$0.02
$-0.68
Q2 24
$0.01
$-0.07
Q1 24
$-0.01
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LXP
LXP
MRVI
MRVI
Cash + ST InvestmentsLiquidity on hand
$170.4M
$216.9M
Total DebtLower is stronger
$1.4B
$291.8M
Stockholders' EquityBook value
$2.0B
$212.4M
Total Assets
$3.5B
$770.6M
Debt / EquityLower = less leverage
0.66×
1.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LXP
LXP
MRVI
MRVI
Q4 25
$170.4M
$216.9M
Q3 25
$229.7M
$243.6M
Q2 25
$71.0M
$269.9M
Q1 25
$70.9M
$285.1M
Q4 24
$101.8M
$322.4M
Q3 24
$55.0M
$578.2M
Q2 24
$48.7M
$573.2M
Q1 24
$293.8M
$561.7M
Total Debt
LXP
LXP
MRVI
MRVI
Q4 25
$1.4B
$291.8M
Q3 25
$1.5B
$292.8M
Q2 25
$1.5B
$293.9M
Q1 25
$1.5B
$294.9M
Q4 24
$1.6B
$295.9M
Q3 24
$521.7M
Q2 24
$522.5M
Q1 24
$523.3M
Stockholders' Equity
LXP
LXP
MRVI
MRVI
Q4 25
$2.0B
$212.4M
Q3 25
$2.1B
$245.4M
Q2 25
$2.1B
$265.9M
Q1 25
$2.1B
$300.6M
Q4 24
$2.1B
$325.3M
Q3 24
$2.1B
$344.9M
Q2 24
$2.1B
$434.7M
Q1 24
$2.2B
$410.7M
Total Assets
LXP
LXP
MRVI
MRVI
Q4 25
$3.5B
$770.6M
Q3 25
$3.7B
$849.2M
Q2 25
$3.7B
$897.0M
Q1 25
$3.8B
$959.8M
Q4 24
$3.8B
$1.0B
Q3 24
$3.9B
$1.3B
Q2 24
$3.9B
$1.4B
Q1 24
$4.2B
$1.4B
Debt / Equity
LXP
LXP
MRVI
MRVI
Q4 25
0.66×
1.37×
Q3 25
0.72×
1.19×
Q2 25
0.72×
1.11×
Q1 25
0.73×
0.98×
Q4 24
0.75×
0.91×
Q3 24
1.51×
Q2 24
1.20×
Q1 24
1.27×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LXP
LXP
MRVI
MRVI
Operating Cash FlowLast quarter
$188.7M
$-22.8M
Free Cash FlowOCF − Capex
$-24.9M
FCF MarginFCF / Revenue
-49.9%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
6.56×
TTM Free Cash FlowTrailing 4 quarters
$-70.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LXP
LXP
MRVI
MRVI
Q4 25
$188.7M
$-22.8M
Q3 25
$63.5M
$-15.2M
Q2 25
$44.3M
$-10.3M
Q1 25
$39.0M
$-9.4M
Q4 24
$211.2M
$-14.6M
Q3 24
$64.6M
$13.1M
Q2 24
$38.5M
$17.4M
Q1 24
$38.9M
$-8.5M
Free Cash Flow
LXP
LXP
MRVI
MRVI
Q4 25
$-24.9M
Q3 25
$-18.1M
Q2 25
$-13.1M
Q1 25
$-14.6M
Q4 24
$-20.5M
Q3 24
$4.5M
Q2 24
$7.9M
Q1 24
$-14.1M
FCF Margin
LXP
LXP
MRVI
MRVI
Q4 25
-49.9%
Q3 25
-43.4%
Q2 25
-27.7%
Q1 25
-31.2%
Q4 24
-36.2%
Q3 24
6.6%
Q2 24
11.4%
Q1 24
-22.0%
Capex Intensity
LXP
LXP
MRVI
MRVI
Q4 25
4.2%
Q3 25
7.0%
Q2 25
6.1%
Q1 25
11.2%
Q4 24
10.3%
Q3 24
12.4%
Q2 24
13.8%
Q1 24
8.8%
Cash Conversion
LXP
LXP
MRVI
MRVI
Q4 25
6.56×
Q3 25
1.75×
Q2 25
1.52×
Q1 25
2.05×
Q4 24
Q3 24
10.18×
Q2 24
7.09×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LXP
LXP

Segment breakdown not available.

MRVI
MRVI

Cygnus Segment$27.2M54%
Other$18.4M37%
Shipping And Handling$4.3M9%

Related Comparisons